Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare an investigational drug (LY2624803) with placebo and with zolpidem in the treatment of outpatients with chronic insomnia.


Clinical Trial Description

Outpatients with chronic insomnia who participate in this study will be treated in each of four 2-week treatment periods with bedtime doses of either placebo, zolpidem, LY2624803 1 mg, or LY2624803 3 mg. Neither patients nor investigators will be told what treatments are being given in any treatment period. A patient who completes all four treatment periods will be treated with placebo in 1, 2, or 3 of the periods; with zolpidem in 0, 1, or 2 of the periods; and with LY2624803 in either 1 or 2 of the periods. No patient will receive placebo for all four of the 2-week treatment periods. All patients will receive LY2624803 for at least one of the four 2-week treatment periods. During each treatment period, patients will record information each morning about their sleep the night before, and each evening about their functioning since waking up. Patients will also wear wrist actigraphy devices to record their physical activity. At the conclusion of each treatment period, patients will answer questions about their sleep, functioning, health, and relative preference for treatments. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00784875
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 2
Start date October 2008
Completion date February 2010

See also
  Status Clinical Trial Phase
Terminated NCT03461666 - Comparison of Efficacy of Behavioral Approaches for Treatment of Insomnia N/A
Recruiting NCT02243501 - Better Nights, Better Days for Typically Developing Children N/A
Completed NCT01636791 - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care Phase 3
Completed NCT00770510 - A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126) Phase 2/Phase 3
Completed NCT00520832 - A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys Phase 2
Recruiting NCT00415714 - Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia N/A
Terminated NCT00420810 - Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED) Phase 3
Completed NCT00178048 - Paroxetine in the Treatment of Chronic Primary Insomnia Phase 4
Completed NCT00816673 - Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs Phase 2
Completed NCT01960452 - A High Density EEG Comparison of Sleep Patterns in Insomnia N/A
Completed NCT01957111 - Metabolomics of Insomnia-Related Hyperarousal N/A
Completed NCT01181232 - A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients Phase 4
Completed NCT00551148 - A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia Phase 2
Completed NCT00397189 - Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients Phase 3
Completed NCT00352144 - 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia Phase 3
Completed NCT02290405 - Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
Completed NCT03314441 - Effects of Regular Practice of Yoga on Subjective and Objective Sleep Quality in Primary Insomnia N/A
Completed NCT00792298 - Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006) Phase 2
Completed NCT01021852 - Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011) Phase 2
Completed NCT01719315 - Neurophysiologic Correlates of Hypersomnia